http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2428983-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4cb413f9adea2c636fbbbc8f394b493 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2006-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c90401eddb225d2156d05097b00d661e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d28f2919f4277791201e23b5e1a3ffb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f4344485e05b654d19029fe29fb78f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78a3a191438796a56132b4bdf71a6f5e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42bbd0b8436f8e0dcd369cd1eaea99b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1abdbc085307c596fb1103a8cb202860 |
publicationDate | 2011-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2428983-C2 |
titleOfInvention | Methods of applying (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thuasolyl)-1,8-naphthydirine-3-carboxylic acid for treatment of cancer |
abstract | FIELD: medicine. n SUBSTANCE: methods in accordance with invention relate to introduction of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methyamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiasolyl)-1,8-naphthydirine-3-carboxylic acid in dose from 50 to 90 mg/m 2 for treatment of myelogenous leukemia leukemia and in dose from 45 to 75 mg/m 2 for treatment of ovary cancer. n EFFECT: extension of arsenal of medications for treatment of ovary cancer and myelogenous leukemia. n 37 cl, 15 tbl, 20 dwg, 11 ex |
priorityDate | 2005-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1335.